Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they produce ions...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect.

Annales de dermatologie et de venereologie·2026
Same author

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Transmissibility model to evaluate transgenerational transmission of environmental effects in quails.

Animal : an international journal of animal bioscience·2025
Same author

Ripretinib-related pyoderma gangrenosum: first description and pathophysiological clues.

Annales de dermatologie et de venereologie·2025
Same author

Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same journal

Comparative study of interstitial brachytherapy and intensity-modulated radiotherapy as tumour bed boost after conservative surgery for breast cancer: Toxicity and cosmetic outcomes.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

[Radiosensitization induced by vemurafenib].

A Ducassou1, I David, M Delannes

  • 1Département de Radiothérapie, Institut Claudius-Regaud, 20-24 Rue du Pont-St-Pierre, 31052 Toulouse cedex, France. ducassou.anne@claudiusregaud.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|July 2, 2013
PubMed
Summary
This summary is machine-generated.

Vemurafenib improves survival in BRAF-mutated melanoma patients but can cause skin side effects. It may also increase radiation sensitivity, requiring awareness from radiation oncologists.

Keywords:
MelanomaMélanomePhénomène de rappelRadiation recallRadiation therapyRadiosensibilisationRadiosentitizationRadiothérapieVemurafenibVémurafénib

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Related Experiment Videos

Last Updated: May 10, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Metastatic melanoma with BRAF mutations presents a therapeutic challenge.
  • Vemurafenib, a BRAF inhibitor, has shown efficacy in improving patient survival.
  • Emerging data suggests potential toxicities associated with targeted therapies.

Observation:

  • Vemurafenib treatment is linked to significant improvements in disease-free and overall survival for metastatic melanoma.
  • Cutaneous side effects are a notable concern with vemurafenib therapy.
  • Concomitant use of vemurafenib and radiotherapy warrants careful consideration due to potential interactions.

Findings:

  • Vemurafenib demonstrates radiosensitizing properties, potentially enhancing the effects of radiation therapy.
  • This radiosensitization can lead to increased toxicity when vemurafenib is combined with radiotherapy.
  • Radiation oncologists must be vigilant regarding these potential toxicities in clinical practice.

Implications:

  • Clinical management of BRAF-mutated melanoma requires balancing the benefits of vemurafenib with its side effect profile.
  • Radiation oncologists need to be informed about vemurafenib's radiosensitizing potential to mitigate risks.
  • Further research is needed to optimize combination strategies and manage toxicities in melanoma treatment.